This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor:—
In the Department of Medicine of the University Hospital Göttingen, we have for 3 years now been employing estriol succinate with great success in the treatment of hemorrhagic diatheses of varying pathogenesis.The most important indications have proved to be thrombocytopenic bleeding, hemorrhagic diatheses resulting from isolated vascular damage, and postoperative capillary hemorrhage. Estriol succinate has also proved to be of value in the prophylaxis of hemorrhagic complications during long-term anticoagulant therapy. The daily dose amounts to 20-30 mg. of estriol succinate administered intravenously. However, even with daily doses as high as 60 mg., no side effects were encountered. Nevertheless, it is inadvisable to exceed the 30 mg. daily dose in women in the menopause when the therapy continues for more than 8 days; otherwise, a proliferation of the endometrium may occur, which can give rise to mild vaginal bleeding. Investigations have been carried out in collaboration
Poliwoda H. Estrogens and Hemorrhage. JAMA. 1962;182(3):315. doi:10.1001/jama.1962.03050420091028
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: